It will have to overcome pricing and reimbursement obstacles, which have plagued similar treatments
Research ArticleEndocrinologyMetabolism Open Access | 10.1172/jci.insight.141851 1 Department of Biomedical Sciences and 2 Baker Institute for Animal Health, Cornell University College of Veterinary Medicine, Ithaca, New York, USA
Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over
[Updated 2019 May 2]
Study link: Tracey Perez Koehlmoos, PhD, MHA Obesity Action Coalition The Obesity Society Obesity Medicine Association Beverly Tchang Melanie Jay, MD, MS Michael Albert MD Michael Glickman, MD Leslie M Golden MD, MPH, FOMA, Dipl
Since tirzepatide is the first in a new drug class, it was deemed particularly important to understand the experience of users